CTOs on the Move


 
Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world`s largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.corium.com
  • 4558, 50th Street Southeast
    Kentwood, MI USA 49512
  • Phone: 616.656.4563

Executives

Name Title Contact Details
Niraj Vasisht
Chief Technology Officer Profile

Similar Companies

Top RX

If you think all generic pharmaceutical distributors are alike, it’s time to think again. We’re TOP RX, a leading national generic distributor that helps more than 5,000 pharmacies keep prices low on more than 2,800 generic pharmaceuticals. We call our company “TOP” for several reasons. We bring value to your business in many ways including our technological solutions, guaranteed product credibility and competitive pricing.

HealthEconomics.Com

HealthEconomics.Com is the worlds most comprehensive and credible website for resources and jobs in healthcare value and market access.

Kamm Consulting

Kamm Consulting is a Apex, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SpineCenterAtlanta

Visit the orthopedic surgeons and spine specialists at Envision Ortho, serving patients in Atlanta, Augusta, and Savannah, Georgia.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.